Copyright Reports & Markets. All rights reserved.

Global Hemoglobinopathy Drugs Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Hemoglobinopathy Drugs Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Hydroxyurea
      • 1.4.3 Glutamine
      • 1.4.4 Zynteglo
      • 1.4.5 Other
    • 1.5 Market by Application
      • 1.5.1 Global Hemoglobinopathy Drugs Market Share by Application (2019-2025)
      • 1.5.2 Sickle Cell Diseases
      • 1.5.3 Thalassemia
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Hemoglobinopathy Drugs Market Size
    • 2.2 Hemoglobinopathy Drugs Growth Trends by Regions
      • 2.2.1 Hemoglobinopathy Drugs Market Size by Regions (2019-2025)
      • 2.2.2 Hemoglobinopathy Drugs Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Hemoglobinopathy Drugs Market Size by by Players
      • 3.1.1 Global Hemoglobinopathy Drugs Revenue by by Players (2014-2019)
      • 3.1.2 Global Hemoglobinopathy Drugs Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Hemoglobinopathy Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Hemoglobinopathy Drugs Key Players Head office and Area Served
    • 3.3 Key Players Hemoglobinopathy Drugs Product/Solution/Service
    • 3.4 Date of Enter into Hemoglobinopathy Drugs Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Hemoglobinopathy Drugs Market Size by Type (2014-2019)
    • 4.2 Global Hemoglobinopathy Drugs Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Hemoglobinopathy Drugs Market Size (2014-2019)
    • 5.2 Hemoglobinopathy Drugs Key Players in North America
    • 5.3 North America Hemoglobinopathy Drugs Market Size by Type
    • 5.4 North America Hemoglobinopathy Drugs Market Size by Application

    6 Europe

    • 6.1 Europe Hemoglobinopathy Drugs Market Size (2014-2019)
    • 6.2 Hemoglobinopathy Drugs Key Players in Europe
    • 6.3 Europe Hemoglobinopathy Drugs Market Size by Type
    • 6.4 Europe Hemoglobinopathy Drugs Market Size by Application

    7 China

    • 7.1 China Hemoglobinopathy Drugs Market Size (2014-2019)
    • 7.2 Hemoglobinopathy Drugs Key Players in China
    • 7.3 China Hemoglobinopathy Drugs Market Size by Type
    • 7.4 China Hemoglobinopathy Drugs Market Size by Application

    8 Japan

    • 8.1 Japan Hemoglobinopathy Drugs Market Size (2014-2019)
    • 8.2 Hemoglobinopathy Drugs Key Players in Japan
    • 8.3 Japan Hemoglobinopathy Drugs Market Size by Type
    • 8.4 Japan Hemoglobinopathy Drugs Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Hemoglobinopathy Drugs Market Size (2014-2019)
    • 9.2 Hemoglobinopathy Drugs Key Players in Southeast Asia
    • 9.3 Southeast Asia Hemoglobinopathy Drugs Market Size by Type
    • 9.4 Southeast Asia Hemoglobinopathy Drugs Market Size by Application

    10 India

    • 10.1 India Hemoglobinopathy Drugs Market Size (2014-2019)
    • 10.2 Hemoglobinopathy Drugs Key Players in India
    • 10.3 India Hemoglobinopathy Drugs Market Size by Type
    • 10.4 India Hemoglobinopathy Drugs Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Hemoglobinopathy Drugs Market Size (2014-2019)
    • 11.2 Hemoglobinopathy Drugs Key Players in Central & South America
    • 11.3 Central & South America Hemoglobinopathy Drugs Market Size by Type
    • 11.4 Central & South America Hemoglobinopathy Drugs Market Size by Application

    12 International Players Profiles

    • 12.1 Novartis
      • 12.1.1 Novartis Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Hemoglobinopathy Drugs Introduction
      • 12.1.4 Novartis Revenue in Hemoglobinopathy Drugs Business (2014-2019))
      • 12.1.5 Novartis Recent Development
    • 12.2 AstraZeneca
      • 12.2.1 AstraZeneca Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Hemoglobinopathy Drugs Introduction
      • 12.2.4 AstraZeneca Revenue in Hemoglobinopathy Drugs Business (2014-2019)
      • 12.2.5 AstraZeneca Recent Development
    • 12.3 Bluebird
      • 12.3.1 Bluebird Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Hemoglobinopathy Drugs Introduction
      • 12.3.4 Bluebird Revenue in Hemoglobinopathy Drugs Business (2014-2019)
      • 12.3.5 Bluebird Recent Development
    • 12.4 Bristol-Myers Squibb
      • 12.4.1 Bristol-Myers Squibb Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Hemoglobinopathy Drugs Introduction
      • 12.4.4 Bristol-Myers Squibb Revenue in Hemoglobinopathy Drugs Business (2014-2019)
      • 12.4.5 Bristol-Myers Squibb Recent Development
    • 12.5 Emmaus Medical
      • 12.5.1 Emmaus Medical Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Hemoglobinopathy Drugs Introduction
      • 12.5.4 Emmaus Medical Revenue in Hemoglobinopathy Drugs Business (2014-2019)
      • 12.5.5 Emmaus Medical Recent Development
    • 12.6 Acceleron Pharma
      • 12.6.1 Acceleron Pharma Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Hemoglobinopathy Drugs Introduction
      • 12.6.4 Acceleron Pharma Revenue in Hemoglobinopathy Drugs Business (2014-2019)
      • 12.6.5 Acceleron Pharma Recent Development
    • 12.7 HemaQuest Pharmaceuticals
      • 12.7.1 HemaQuest Pharmaceuticals Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Hemoglobinopathy Drugs Introduction
      • 12.7.4 HemaQuest Pharmaceuticals Revenue in Hemoglobinopathy Drugs Business (2014-2019)
      • 12.7.5 HemaQuest Pharmaceuticals Recent Development
    • 12.8 Eli Lilly and Company
      • 12.8.1 Eli Lilly and Company Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Hemoglobinopathy Drugs Introduction
      • 12.8.4 Eli Lilly and Company Revenue in Hemoglobinopathy Drugs Business (2014-2019)
      • 12.8.5 Eli Lilly and Company Recent Development
    • 12.9 Celgene
      • 12.9.1 Celgene Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Hemoglobinopathy Drugs Introduction
      • 12.9.4 Celgene Revenue in Hemoglobinopathy Drugs Business (2014-2019)
      • 12.9.5 Celgene Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      This report focuses on the global Hemoglobinopathy Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hemoglobinopathy Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Novartis
      AstraZeneca
      Bluebird
      Bristol-Myers Squibb
      Emmaus Medical
      Acceleron Pharma
      HemaQuest Pharmaceuticals
      Eli Lilly and Company
      Celgene

      Market segment by Type, the product can be split into
      Hydroxyurea
      Glutamine
      Zynteglo
      Other

      Market segment by Application, split into
      Sickle Cell Diseases
      Thalassemia

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Hemoglobinopathy Drugs status, future forecast, growth opportunity, key market and key players.
      To present the Hemoglobinopathy Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Hemoglobinopathy Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now